Business
Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial
VAUGHAN, Ontario, September 11, 2025--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the American Journal of Ophthalmology has published results of the pivotal U.S. clinical trial of the enVista Envy novel full visual range intraocular lens. The study compared visual, refractive and patient-reported outcomes following implantation of enVista Envy and the enVista® monofocal IOL in cataract
About this update from Bausch + Lomb Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":4152,"height":327,"url":"https://media.zenfs.com/en/business-wire.com/4f68204e3ffcdf0f923f85e5cb681951"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9hUDkcl3Vc2sLAVPf7t9VQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTc2O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/4f68204e3ffcdf0f923f85e5cb681951","width":960,"height":76},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/TGlBya3DIxiyIAT5_kZRXQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xOTA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/4f68204e3ffcdf0f923f85e5cb681951","width":1200,"height":95}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"enVista Envy full range of vision intraocular lens (IOL) met all primary efficacy and safety endpoints in multicenter study","length":123,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Results show that enVista Envy IOLs deliver excellent visual performance, good contrast sensitivity and a favorable dysphotopsia profile","length":136,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":259,"olType":false},{"type":"text","content":"VAUGHAN, Ontario, September 11, 2025--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the American Journal of Ophthalmology has published results of the pivotal U.S. clinical trial of the enVista Envy novel full visual range intraocular lens. The study compared visual, refractive and patient-reported outcomes following implantation of enVista Envy and the enVista® monofocal IOL in cataract surgery patients.","length":535,"tagName":"p"},{"type":"text","content":""enVista Envy has been well received as the first premium IOL on the widely used enVista platform," said Luc Bonnefoy, president, Surgical, Bausch + Lomb. "Results of this study confirm the advantages that this lens offers – continuous range of vision from distance to near with excellent dysphotopsia tolerance."","length":333,"tagName":"p"},{"type":"text","content":"In the multicenter, prospective, masked, controlled trial, investigators randomized 501 cataract patients into two groups, one of which receiv...